


INFORMATION DISCLOSURE
CITATION IN AN
APPLICATION



(P/O-1449)

ATTY. DOCKET NO.
58532-012

SERIAL NO.
09/884,466

RECEIVED

NOV 13 2001

APPLICANT
Arthur L. HERBST, et al.

TECH CENTER 1600/20

FILING DATE
June 20, 2001

GROUP
1633

U.S. PATENT DOCUMENTS




EXAMINER'S INITIALS	PATENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE
aqa	6,239,137 B1	05/29/2001	KARMALI et al.			
	5,486,534	01/23/1996	LEE et al.			
	5,972,986	10/26/1999	SEIBERT et al.			
	5,760,068	06/02/1998	TALLEY et al.			
	5,563,165	10/8/1996	TALLEY et al.			
	5,466,823	11/14/1995	TALLEY et al.			
	6,046,196	04/04/2000	HEFTI			
	5,691,374	11/25/1997	BLACK et al.			
	6,046,191	04/04/2000	HAMLEY et al.			
	5,474,995	12/12/1995	DUCHARME et al.			
	6,048,850	04/11/2000	YOUNG et al.			

FOREIGN PATENT DOCUMENTS

EXAMINER'S INITIALS	PATENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	Translation	
						Yes	No
10	WO 98/16227	04/23/1998	WIPO/OMP, PCT				

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

10 10 10	"Response: re: Enhancement of Tumor Response to gamma-Radiation by an Inhibitor of Cyclooxygenase-2 Enzyme", Milas et al., <i>Journal of the National Cancer Institute</i> , Vol. 92, No. 4, pp. 346-347, February 16, 2000
	"On radiation damage to normal tissues and its treatment. II. Anti-inflammatory drugs", Michalowski, A.S., <i>Acta Oncologica</i> , 33(2): 139-157, 1994, (Abstract)
	"Preferential Enhancement of Tumor Radioresponse by a Cyclooxygenase-2 Inhibitor", Kishi et al., <i>Cancer Research</i> , 60, pp. 1326-1331, March 1, 2000
	"Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors", Masferrer et al., <i>Cancer Research</i> , Vol. 60, No. 5, pp. 1306-1311, March 1, 2000 (Abstract)

✓	"The cyclooxygenase-2 inhibitor celecoxib induces apoptosis by blocking akt activation in human prostate cancer cells independently of bcl-2", Hsu et al., <i>J Biol Chem</i> , Vol. 275, No. 15, pp. 11397-11403, April 14, 2000 (Abstract)
✓	"Chemoprevention of breast cancer in rats by celecoxib, a cyclooxygenase 2 inhibitor", Harris et al., <i>Cancer Research</i> , Vol. 60, No. 8, pp.2101-2103, April 15, 2000 (Abstract)
✓	"Ketoconazole attenuates radiation-induction of tumor necrosis factor", Hallahan et al., <i>International Journal of Radiation Oncology, Biology, Physics</i> , Vol. 29, No. 4, pp. 777-780, July 1, 1994 (Abstract)
	"Protective ability of acetylsalicylic acid (aspirin) to scavenge radiation induced free radicals in 774A.1 macrophage cells", Saini et al., <i>Research Communications in Molecular Pathology & Pharmacology</i> , Vol. 101, No. 3, pp. 259-268, September 1998 (Abstract)
✓	"Molecular pathology of cyclooxygenase-2 in neoplasia", Fosslie, <i>Annals of Clinical and Laboratory Science</i> , Vol. 30, No. 1, pp. 3-21, January 2000 (Abstract)
✓	"Chemoprevention of colon cancer by specific cyclooxygenase-2 inhibitor, celecoxib, administered during different stages of carcinogenesis", Reddy et al, <i>Cancer Research</i> , Vol. 60, No. 2, pp. 293-297, January 15, 2000 (Abstract)
✓	"Chemopreventative activity of celecoxib, a specific cyclooxygenase-2 inhibitor, and infomethacin against ultraviolet light-induced carcinogenesis", Fischer et al., <i>Mol Carcinog</i> , Vol. 25, No. 4, pp. 231-240, August 1999 (Abstract)
✓	"Inhibition of angiogenesis by nonsteroidal anti-inflammatory drugs: insight into mechanisms and implications for cancer growth and ulcer healing", Jones et al., <i>Nat Med</i> , Vol. 5, No. 12, 1418-1423, December 1999 (Abstract)
✓	"Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, against colon carcinogenesis", Kawamori et al., <i>Cancer Research</i> , Vol. 58, No. 3, pp. 409-412, February 1, 1998 (Abstract)
✓	"Over-expression of cyclooxygenase-2 in Human prostate adenocarcinoma", Gupta et al., <i>Prostate</i> , Vol. 42, No. 1, pp. 73-78, January 1, 2000 (Abstract)
EXAMINER 	DATE CONSIDERED 

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.